JP2015512630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512630A5 JP2015512630A5 JP2015500494A JP2015500494A JP2015512630A5 JP 2015512630 A5 JP2015512630 A5 JP 2015512630A5 JP 2015500494 A JP2015500494 A JP 2015500494A JP 2015500494 A JP2015500494 A JP 2015500494A JP 2015512630 A5 JP2015512630 A5 JP 2015512630A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- mutation
- mll
- dnmt3a
- npm1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 50
- 230000004083 survival effect Effects 0.000 claims description 42
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 32
- -1 KIT Proteins 0.000 claims description 29
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 27
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 27
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 26
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 claims description 24
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 claims description 24
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 claims description 23
- 101000692980 Homo sapiens PHD finger protein 6 Proteins 0.000 claims description 21
- 102100022678 Nucleophosmin Human genes 0.000 claims description 21
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 18
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims description 18
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims description 18
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 17
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 17
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 16
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 16
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims description 14
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims description 14
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims description 14
- 108700020467 WT1 Proteins 0.000 claims description 14
- 101150084041 WT1 gene Proteins 0.000 claims description 14
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 claims description 13
- 102100026365 PHD finger protein 6 Human genes 0.000 claims description 13
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 12
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 claims description 12
- 102100029974 GTPase HRas Human genes 0.000 claims description 12
- 102100030708 GTPase KRas Human genes 0.000 claims description 12
- 102100039788 GTPase NRas Human genes 0.000 claims description 12
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 12
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 12
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 12
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 12
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 12
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 12
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims description 12
- 230000002559 cytogenic effect Effects 0.000 claims description 12
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 claims description 10
- 101150080074 TP53 gene Proteins 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 8
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 7
- 229960000975 daunorubicin Drugs 0.000 claims description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 7
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 5
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 5
- 239000003817 anthracycline antibiotic agent Substances 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 3
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 102100022748 Wilms tumor protein Human genes 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 7
- 210000001185 bone marrow Anatomy 0.000 claims 7
- 238000002512 chemotherapy Methods 0.000 claims 7
- 206010064571 Gene mutation Diseases 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 210000005087 mononuclear cell Anatomy 0.000 claims 5
- 206010053871 Trisomy 8 Diseases 0.000 claims 4
- 208000034298 trisomy chromosome 8 Diseases 0.000 claims 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 3
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 3
- 229960000908 idarubicin Drugs 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- 101150110046 Dnmt3a gene Proteins 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 229940009456 adriamycin Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 229960001156 mitoxantrone Drugs 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- 101150083701 npm1 gene Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 101150061453 Cebpa gene Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 102000040856 WT1 Human genes 0.000 description 5
- 208000037516 chromosome inversion disease Diseases 0.000 description 4
- 108010072732 Core Binding Factors Proteins 0.000 description 3
- 102000006990 Core Binding Factors Human genes 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 101150101097 ASXL1 gene Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 101100110209 Homo sapiens ASXL1 gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150117530 PHF6 gene Proteins 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200116484 rs121913502 Human genes 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609723P | 2012-03-12 | 2012-03-12 | |
| US61/609,723 | 2012-03-12 | ||
| PCT/US2013/030208 WO2013138237A1 (en) | 2012-03-12 | 2013-03-11 | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512630A JP2015512630A (ja) | 2015-04-30 |
| JP2015512630A5 true JP2015512630A5 (enExample) | 2016-05-12 |
Family
ID=49161688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500494A Pending JP2015512630A (ja) | 2012-03-12 | 2013-03-11 | 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150031641A1 (enExample) |
| EP (1) | EP2825669A4 (enExample) |
| JP (1) | JP2015512630A (enExample) |
| CN (1) | CN104508143A (enExample) |
| AU (1) | AU2013232379A1 (enExample) |
| CA (1) | CA2867375A1 (enExample) |
| WO (1) | WO2013138237A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036325B1 (ru) | 2014-03-14 | 2020-10-27 | Аджиос Фармасьютикалз, Инк. | Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1 |
| WO2016086197A1 (en) | 2014-11-25 | 2016-06-02 | The Brigham And Women's Hospital, Inc. | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease |
| EP3224380A1 (en) | 2014-11-25 | 2017-10-04 | The Broad Institute Inc. | Clonal haematopoiesis |
| CN104774954A (zh) * | 2015-04-23 | 2015-07-15 | 上海允英医疗科技有限公司 | 用于hras突变检测的引物、探针及检测试剂盒 |
| UA123401C2 (uk) | 2015-10-15 | 2021-03-31 | Аджиос Фармасьютікалз, Інк. | Комбінована терапія для лікування злоякісних пухлин |
| ES2897959T3 (es) | 2015-10-15 | 2022-03-03 | Servier Lab | Terapia de combinación para tratar neoplasias malignas |
| CA3219061A1 (en) * | 2015-11-11 | 2017-05-18 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
| WO2017084027A1 (zh) * | 2015-11-17 | 2017-05-26 | 安诺优达基因科技(北京)有限公司 | 一种用于急性髓细胞白血病预后分层的试剂盒及检测方法 |
| IL299563A (en) * | 2015-12-04 | 2023-02-01 | Agios Pharmaceuticals Inc | Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| KR101877607B1 (ko) * | 2016-03-03 | 2018-07-12 | 포항공과대학교 산학협력단 | 인슐린／ｉｇｆ―1 수용체 결핍 돌연변이체의 발달결함만 특이적으로 억제된 예쁜꼬마선충 |
| CN105861674A (zh) * | 2016-04-27 | 2016-08-17 | 上海荻硕贝肯生物科技有限公司 | 用于检测与aml预后相关的基因突变的引物、试剂盒及方法 |
| CN105969892B (zh) * | 2016-07-14 | 2019-07-19 | 北京大学人民医院 | Csrp2在作为评估成人b-all患者预后风险标记物中的应用 |
| CN106381332A (zh) * | 2016-08-31 | 2017-02-08 | 天津协和华美医学诊断技术有限公司 | 一种检测aml相关基因群的检测试剂盒 |
| CN108778276A (zh) | 2016-11-02 | 2018-11-09 | 安罗格制药有限责任公司 | 用于治疗flt3突变型增殖性疾患相关突变的克莱拉尼 |
| CN107641650B (zh) * | 2017-08-24 | 2020-05-08 | 中国人民解放军总医院 | Nr1h3在急性髓系白血病精准靶向检测及预后评估中的应用 |
| US10460446B2 (en) * | 2017-10-16 | 2019-10-29 | Nant Holdings Ip, Llc | Image-based circular plot recognition and interpretation |
| CN107841556B (zh) * | 2017-12-19 | 2020-12-01 | 武汉大学 | 一种基于C/EBPα和IGF1R基因筛选药物发育毒性的试剂盒及应用 |
| CN107893118A (zh) * | 2017-12-25 | 2018-04-10 | 合肥艾迪康临床检验所有限公司 | 检测phf6点突变的方法和引物 |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| CN109172597B (zh) * | 2018-09-06 | 2020-12-18 | 清华大学深圳研究生院 | 调节rDNA基因染色质组蛋白甲基化水平的物质及其应用 |
| CN110124038A (zh) * | 2019-05-08 | 2019-08-16 | 山东大学齐鲁医院 | 腺苷酸琥珀酸合成酶基因和/或其编码的蛋白的新应用 |
| US20230175068A1 (en) * | 2020-04-15 | 2023-06-08 | Centre National De La Recherche Scientifique | Prognosis method of acute myeloid leukaemia |
| CN111560438B (zh) * | 2020-06-11 | 2024-01-19 | 迈杰转化医学研究(苏州)有限公司 | 检测aml预后相关基因突变的引物组合物、试剂盒及其应用 |
| KR102317670B1 (ko) * | 2020-07-30 | 2021-10-26 | 서울대학교산학협력단 | Phf6를 표적으로 하는 히스톤 h2b 에피제네틱 조절제 스크리닝 방법 |
| CN112708675A (zh) * | 2020-12-25 | 2021-04-27 | 中山大学肿瘤防治中心 | 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用 |
| CN112626215B (zh) * | 2020-12-30 | 2023-03-24 | 武汉康圣达医学检验所有限公司 | Aml预后相关基因表达检测试剂盒 |
| CN115216541A (zh) * | 2021-04-15 | 2022-10-21 | 复旦大学附属华山医院 | 一组白血病标志物及应用 |
| CN113764038B (zh) * | 2021-08-31 | 2023-08-22 | 华南理工大学 | 构建骨髓增生异常综合征转白基因预测模型的方法 |
| CN115323051B (zh) * | 2022-02-22 | 2023-04-07 | 天津见康华美医学诊断技术有限公司 | 一种急性髓系白血病检测探针组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919623A (en) * | 1994-04-27 | 1999-07-06 | St. James's And Seacroft University Hospitals Nhs Trust | Nucleic acid mutation assays |
| US20130059301A1 (en) * | 2010-02-12 | 2013-03-07 | Institut Paoli-Calmettes | Asxl1 as a new diagnostic marker of myeloid neoplasms |
| BR112013016708B1 (pt) * | 2010-12-30 | 2021-08-17 | Foundation Medicine, Inc | Otimização de análise multigene de amostras de tumor |
-
2013
- 2013-03-11 EP EP13760340.3A patent/EP2825669A4/en not_active Withdrawn
- 2013-03-11 AU AU2013232379A patent/AU2013232379A1/en not_active Abandoned
- 2013-03-11 WO PCT/US2013/030208 patent/WO2013138237A1/en not_active Ceased
- 2013-03-11 US US14/384,580 patent/US20150031641A1/en not_active Abandoned
- 2013-03-11 CN CN201380024896.0A patent/CN104508143A/zh active Pending
- 2013-03-11 JP JP2015500494A patent/JP2015512630A/ja active Pending
- 2013-03-11 CA CA2867375A patent/CA2867375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512630A5 (enExample) | ||
| AU2022228167B2 (en) | Methods and materials for assessing loss of heterozygosity | |
| Won et al. | Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor | |
| Andersen et al. | Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | |
| JP6900314B2 (ja) | 膀胱癌の治療、診断、及び予後判定方法 | |
| Boyd et al. | Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32. 3 as being genes in regions associated with adverse survival | |
| EP3198026B1 (en) | Method of determining pik3ca mutational status in a sample | |
| JP6709541B2 (ja) | 大腸癌に対する薬物療法の感受性を予測する方法 | |
| EP2825669A1 (en) | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia | |
| Beuselinck et al. | Validation of VEGFR 1 rs9582036 as predictive biomarker in metastatic clear‐cell renal cell carcinoma patients treated with sunitinib | |
| Buckingham et al. | The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib | |
| AU2004216231B2 (en) | Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus | |
| EP3945135A1 (en) | Biomarkers for diagnosing and monitoring lung cancer | |
| Veedu et al. | Precision Oncology in Colorectal Cancers-Therapeutics and Beyond (CME article) | |
| Lewandowski et al. | Circulating tumor DNA–from biology to potential clinical applications in diffuse large B-cell lymphomas | |
| Mendelaar | Genomic characterization in oncology: Exploring the tide of personalized medicine | |
| HK40120571A (en) | Methods and materials for assessing loss of heterozygosity | |
| JP5967699B2 (ja) | 遺伝子発現解析による大腸がんの病型分類に基づく抗癌剤応答性及び予後の予測方法 | |
| Okamoto et al. | Clinical utility of quasi-monomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01 | |
| Honkala | Liquid biopsy in breast cancer: identifying circulating tumor DNA from breast cancer patient serum samples using PIK3CA-H1047R mutation specific castPCR | |
| Suhaimi | Non-Invasive Evaluation of Colorectal Cancer | |
| Lambrechts et al. | 1412 POSTER Genetic Markers in Relation to Bevacizumab-induced Hypertension | |
| NZ625468B2 (en) | Methods and materials for assessing loss of heterozygosity |